Showing 2381-2390 of 4065 results for "".
- Empowering Rheumatic Health: The Role of Physical Activity and Latest Innovationshttps://reachmd.com/news/empowering-rheumatic-health-the-role-of-physical-activity-and-latest-innovations/2483453/Rheumatology is increasingly integrating structured exercise to improve outcomes, and the central question is how clinicians are translating these evolving insights into everyday care. Time constraints, comorbidities, and variability in access are complicating how ca
- Evaluating COVID Vaccine Safety for Pregnant Women and Children: Latest Findingshttps://reachmd.com/news/evaluating-covid-vaccine-safety-for-pregnant-women-and-children-latest-findings/2483454/Vaccination efforts in pregnancy and pediatric populations are underpinned by robust studies, supporting safety while addressing lingering concerns. Surveillance and education remain key components in increasing vaccine uptake among hesitant groups. Recent studies af
- Allergan Aesthetics Casting Breast Reconstruction, Augmentation Patients for Latest Campaignhttps://reachmd.com/news/allergan-aesthetics-casting-breast-reconstruction-augmentation-patients-for-latest-campaign/2473743/Allergan Aesthetics wants to hear from patients who have experienced a Natrelle breast reconstruction or augmentation. The AbbVie company is searching for women to share their inspiring stories and be featured in an upcoming Allergan Aesthetics campaign. The campaign is an extension of th
- Sweeping Review Reveals Latest Evidence on the Diagnosis, Treatment, and Monitoring of ADHDhttps://reachmd.com/news/sweeping-review-reveals-latest-evidence-on-the-diagnosis-treatment-and-monitoring-of-adhd/2462454/Hundreds of studies are published each year on attention deficit hyperactivity disorder (ADHD), but more work is needed to ensure those findings improve lives. With input from expert stakeholders across the field, researchers at the Southern California Evidence Review Center, part of the
- Latest COVID-19 Booster Halves Risk of Moderate or Severe Disease in Adultshttps://reachmd.com/news/latest-covid-19-booster-halves-risk-of-moderate-or-severe-disease-in-adults/2457423/The most recent COVID-19 booster shot reduces adults' risk of moderate or severe COVID by more than half, according to a new nationwide data study from September 2023 through January 2024, a period of JN.1 variant dominance. The new stud
- Two Pediatric Medical Device Companies Receive Prestigious Award at MedTech Color Edition of Make Your Medical Device Pitch For Kids!™ competitionhttps://reachmd.com/news/two-pediatric-medical-device-companies-receive-prestigious-award-at-medtech-color-edition-of-make-your-medical-device-pitch-for-kidstm-competition/2462351/Alliance for Pediatric Device Innovation (APDI), a federally funded consortium led by Children’s National Hospital, and member MedTech Color announce the winners of the latest Make Your Medical Device Pitch for Kids!™ competitio
- Switching to Twice-Yearly Depemokimab in Severe Asthmahttps://reachmd.com/news/twice-yearly-depemokimab-severe-asthma/2487242/Key Takeaways In severe asthma, switching to depemokimab every 26 weeks was associated with low clinically significant exacerbation rates over 52 weeks, but the noninferiority criterion was not met. Health-related quality of life, asthma control, and l
- Review: Seven HS PROMs Meet COSMIN Standards for Clinical Usehttps://reachmd.com/news/review-seven-hs-proms-meet-cosmin-standards-for-clinical-use/2485535/A new systematic review and meta-analysis found seven clinically useful tools for capturing and analyzing hidradenitis suppurativa (HS)–specific patient-reported outcome measures (PROMs). The review, which included 26 studies a
- New Research Identifies Critical Gaps in Mental Health Care for Adults with Schizophrenia Spectrum Disordershttps://reachmd.com/news/new-research-identifies-critical-gaps-in-mental-health-care-for-adults-with-schizophrenia-spectrum-disorders/2468296/New research finds that adults with schizophrenia spectrum disorders have high rates of comorbid mental and substance use disorders and significant social and economic disadvantages, and only 26% received minimally adequate treatment. Meeting th
- MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain with Oral Ketamir-2 in Breakthrough Studyhttps://reachmd.com/news/mira-pharmaceuticals-achieves-100-reversal-of-neuropathic-pain-with-oral-ketamir-2-in-breakthrough-study/2468049/Study Highlights Superior Efficacy of Ketamir-2 Over Oral Ketamine, Achieving Full Normalization of Pain ThresholdsMIAMI, FL / ACCESSWIRE / August 26, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pha